AHMED M. ELSHAZLY^1,2, TUONG VI V. NGUYEN¹, DAVID A. GEWIRTZ^1,*

Oncology Research, Vol.30, No.1, pp. 1-12, 2022, DOI:10.32604/or.2022.026459

Abstract PARP inhibitors have proven to be effective in conjunction with conventional therapeutics in the treatment of various solid as well as hematologic malignancies, particularly when the tumors are deficient in DNA repair pathways. However, as the case with other chemotherapeutic agents, their effectiveness is often compromised by the development of resistance. PARP inhibitors have consistently been reported to promote autophagy, a process that maintains cellular homeostasis and acts as an energy source by the degradation and reutilization of damaged subcellular organelles and proteins. Autophagy can exhibit different functional properties, the most prominent being cytoprotective. In addition, both cytotoxic and non-protective… More >

QIANG WANG^#, GUO ZHAO^#, LONGXIANG XIE^#, XUAN LI, XIXI YU, QIONGSHAN LI, BAOPING ZHENG, ZULIPINUER WUSIMAN, XIANGQIAN GUO^*

BIOCELL, Vol.47, No.2, pp. 367-371, 2023, DOI:10.32604/biocell.2023.025310

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen of the ongoing coronavirus disease 2019 (COVID-19) global pandemic. Here, by centralizing published cell-based experiments, clinical trials, and virtual drug screening data from the NCBI PubMed database, we developed a database of SARS-CoV-2 inhibitors for COVID-19, dbSCI, which includes 234 SARS-CoV-2 inhibitors collected from publications based on cell-based experiments, 81 drugs of COVID-19 in clinical trials and 1305 potential SARS-CoV-2 inhibitors from bioinformatics analyses. dbSCI provides four major functions: (1) search the drug target or its inhibitor for SARS-CoV-2, (2) browse target/inhibitor information collected from cell experiments, clinical trials, and… More >

MOTAWA E. EL-HOUSEINI¹, MOSTAFA S. ARAFAT², AHMED M. EL-HUSSEINY³, ISLAM M. KASEM², MAHMOUD M. KAMEL⁴, AHMED H. EL-HABASHY⁵, MEDHAT M. KHAFAGY⁶, ENAS M. RADWAN⁴, MAHA H. HELAL⁷, MONA S. ABDELLATEIF^1,*

Oncology Research, Vol.29, No.5, pp. 319-329, 2021, DOI:10.32604/or.2022.025249

Abstract Immunotherapy becomes a promising line of treatment for breast cancer (BC) however, its success rate is still limited. Methods: The study was designed to optimize the condition for producing an effective dendritic cell (DCs) based immunotherapy by using DCs and T lymphocytes together with tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating DCs (TIDCs), treated with anti-PD1 and anti-CTLA4 monoclonal antibodies. This mixture of immune cells was co-cultured with autologous breast cancer cells (BCCs) isolated from 26 BC females. Results: There was a significant upregulation of CD86 and CD83 on DCs (P = 0.001 and 0.017, respectively), similarly upregulation of CD8, CD4 and… More >

Amir Imran Faisal Hamdi, Johnson Stanslas^*

Oncologie, Vol.24, No.2, pp. 185-194, 2022, DOI:10.32604/oncologie.2022.023629

Abstract KRAS mutations are among the most common oncogenic abnormalities in cancer. Until recently, drug discovery pursuing KRAS did not produce therapeutic benefits for patients. Specific KRAS inhibitors, such as sotorasib and adagrasib, which bind covalently to codon 12 of substituted glycine to cysteine residue of the protein (G12C), have been approved by the FDA recently for the treatment of lung cancers. Binding of these drugs to the protein inhibits the activation of the GDP-bound inactive state to the GTP-bound active state. Phase 1/2 trials have shown potential anti-tumor activity, particularly in patients with previously treated non-small cell lung cancer. Acquired… More >

Yanhui Li^*†, Su Dong^*†, Arya Tamaskar^†, Heather Wang^†, Jing Zhao^†, Haichun Ma^*, Yutong Zhao^†

Oncology Research, Vol.28, No.5, pp. 497-507, 2020, DOI:10.3727/096504020X15929939001042

Abstract Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 85% of all lung carcinomas. The hepatocyte growth factor receptor (c-Met) has been considered as a potential therapeutic target for NSCLC. Proteasome inhibition induces cell apoptosis and has been used as a novel therapeutic approach for treating diseases including NSCLC; however, the effects of different proteasome inhibitors on NSCLC have not been fully investigated. The aim of this study is to determine a precise strategy for treating NSCLC by targeting c-Met using different proteasome inhibitors. Three proteasome inhibitors, bortezomib, MG132, and ONX 0914, were… More >

Shuaibin Luo¹, Xuemei Zhang², Kang He¹, Juan Zou^1,*, Chang-An Geng^2,*

Phyton-International Journal of Experimental Botany, Vol.91, No.8, pp. 1809-1816, 2022, DOI:10.32604/phyton.2022.020935

Abstract Uncaria rhynchophylla (Gouteng) is a famous traditional Chinese medicine used for psychiatric and hypotensive purposes in China. In this study, the ethyl acetate (EtOAc) part of U. rhynchophylla was revealed with protein tyrosine phosphatase 1B (PTP1B) inhibitory activity. Subsequent investigation on the EtOAc part yielded one new triterpenoid, 3β-formyloxy-6β,19α-dihydroxyurs-12-en-28-oic acid (1) and four known ones, 3β,6β,19α-trihydroxyurs-12-en-28-oic acid (2), 2-oxopomolic acid (3), 3β,19α-dihydroxy-6-oxo-olean-12-en-28-oic acid (4) and sumaresinolic acid (5). The structure of compound 1 was determined by extensive HRESIMS, IR, 1D and 2D NMR spectroscopic analyses. Two ursane-type triterpenoids (2 and 3) showed selective inhibition on PTP1B with IC₅₀ values of… More >

Hao Luo^1,#,*, Yanjie Ji^2,#, Xinrong Gao¹, Xinying Liu¹, Yunzhao Wu³, Yingli Wu^3,*

Oncologie, Vol.24, No.1, pp. 85-99, 2022, DOI:10.32604/oncologie.2022.021705

Abstract The ubiquitin-proteasome system (UPS) is an important pathway for cellular protein degradation. The components of this pathway, including the proteasome, ubiquitinase, and deubiquitinase, are highly specialized and strictly regulated. The ubiquitin-specific protease 2 (USP2) belongs to the ubiquitin-specific proteases, a subgroup of deubiquitinating enzymes. USP2 plays essential roles in regulating cell survival, cell cycle, circadian rhythm, cell metabolism, inflammatory response, antiviral response, and metastasis by interacting with certain proteins such as Cyclin D1, PER1, CRY1, HDM2/p53, FASN, LDLR, TRAF6, TBK1, and TGFBR1-TGFBR2 complex. Elevation of USP2 has been observed in a variety of cancers, including glioma, testicular cancer, breast cancer,… More >

Elsa Maitre, Xavier Troussard^*

Oncologie, Vol.24, No.1, pp. 3-24, 2022, DOI:10.32604/oncologie.2022.021490

Abstract Hairy cell leukemia (LT) accounts for 2% of all leukemias. The diagnosis is based on the presence in the blood and/ or the marrow of hairy cells expressing CD103, CD123, CD11c and CD25. The BRAF^V600E mutation, a molecular marker of the disease, is present in more than 80% of cases. LT should be distinguished from other chronic B-cell lymphoproliferative disorders, including the variant form of hairy cell leukemia (HCL-V) and diffuse splenic red pulp lymphoma (DSRPL). Progress has recently been made in the management of patients. The purine analogues (PNAs) in monotherapy, deoxycoformycin (DCF) or 2-chloro-deoxyadenosine (CDA), remain the first-line… More >

YUHUA ZOU^1,#, LEI ZHANG^2,#, XIN ZHONG^3,*

BIOCELL, Vol.46, No.5, pp. 1309-1317, 2022, DOI:10.32604/biocell.2022.018167

Abstract Renal cell carcinoma (RCC) has a poor prognosis due to limited diagnosis and treatment. Thus, it is necessary to find novel prognostic biomarkers and therapeutic targets. The aberrant expression of microRNAs plays an important role in RCC oncogenesis. Tissue inhibitors of metalloproteinase 3 (TIMP3) acts as a downstream target of miR-181b. The aim of this study was to understand the role and molecular mechanism of miR-181b in RCC oncogenesis. The results showed that miR-181b expression was significantly higher in RCC tumour tissues, especially in those with significant invasion or metastasis. miR-181b overexpression promoted proliferation and migration of the RCC cell… More >

Raghav Mishra^1,2,*, Nitin Kumar³, Neetu Sachan²

Oncologie, Vol.23, No.4, pp. 493-514, 2021, DOI:10.32604/oncologie.2021.018532

Abstract The relevance of Retinoic acid receptor-related orphan receptors in cancer progression has sparked interest in developing multifunctional therapeutics. In the search for potentially active novel compounds with anticancer characteristics, the Gewald reaction was employed to develop different thiophene derivatives (8a–8i). Physicochemical and spectroanalytical investigations verified the molecular structures of the synthesized derivatives. Using an in vitro primary anticancer assay, NCI chose all of the synthesized molecules as prototypes and assessed their anticancer efficacy against a panel of various cancer cell lines representing nine distinct neoplasms. The compounds were found to have a wide range of anticancer activity. Following significant anticancer… More >